Physician profile
Alex Lima
NPI 1356389381
$4,410.60
in general payments reported to CMS, 2019-2025
23 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $417 · 2021: $819 · 2022: $692 · 2023: $761 · 2024: $965 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,191.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,079.77 | 2020-2025 | Jardiance |
| Antares Pharma, INC. | $457.81 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Novo Nordisk INC | $363.35 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $328.34 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $294.33 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $282.34 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $232.09 | 2023-2025 | |
| Horizon Therapeutics Plc | $220.78 | 2019-2022 | |
| Amgen INC. | $214.26 | 2020-2025 | Repatha, Otezla, Repatha |
| Sumitomo Pharma America, INC. | $197.50 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.09 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $115.69 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $81.07 | 2021-2022 | |
| Halozyme INC | $63.60 | 2023 | |
| Pfizer INC. | $62.31 | 2019-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $53.32 | 2024 | Edarbi, Edarbyclor |
| Astellas Pharma US INC | $35.91 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $34.31 | 2019-2023 | Linzess |
| Janssen Pharmaceuticals, INC | $30.68 | 2020 | |
| Esperion Therapeutics, INC. | $21.93 | 2021 | |
| Seqirus USA INC | $18.06 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.99 | 2019 | |
| Amarin Pharma, INC. | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Lima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.